Connect Biopharma Holdings Ltd. (CNTB)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
Connect Biopharma Touts Rademikibart's Edge as SEABREEZE Data Looms in 2026
Connect Biopharma NASDAQ: CNTB Chief Executive Officer Barry Quart said the company's rademikibart program continues to show a differentiated clinical and mechanistic profile as the company awaits mid-2026 data from its SEABREEZE study.
Connect Biopharma: New Market Opportunity In The Emergency Setting
Connect Biopharma Holdings is rated a risky Buy, with high upside potential hinging on mid-2026 Phase 2 trial results for rademikibart. Rademikibart has shown superior efficacy and safety to Dupixent in China Phase 3 trials, with commercialization led by Simcere and low-double-digit royalties to CNTB. CNTB is targeting the emergency asthma and COPD settings in the US, a market with no approved biologics, and expects pivotal Phase 2 data in mid-2026.
Connect Biopharma Holdings Limited (CNTB) Discusses Development Strategy for Next-Generation Biologic Targeting Acute and Chronic Respiratory Diseases Transcript
Connect Biopharma Holdings Limited ( CNTB ) Discusses Development Strategy for Next-Generation Biologic Targeting Acute and Chronic Respiratory Diseases November 3, 2025 4:15 PM EST Company Participants Barry Quart - CEO & Director Conference Call Participants Craig Brelsford Presentation Craig Brelsford Hello. This is Craig Brelsford with RedChip Companies.
Connect Biopharma Holdings Ltd. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Point72 Asset Management LP Point72 Asset Management LP | 19,766 | $55,087.07 | $46,944.25 | -$8,142.82 | -14.78% |
| RO Regan O'Neill Burkehill Global Management LP | 150,000 | $393,000 | $363,750 | -$29,250 | -7.44% |
 Jim Harding Propel Bio Management LLC | 209,493 | $553,909 | $482,881.36 | -$71,027.64 | -12.82% |
 Michael Souza Koa Wealth Management, LLC | 49,600 | $74,896 | $114,328 | $39,432 | 52.65% |
 Zachary Canonico DIADEMA PARTNERS LP | 200,690 | $525,808 | $460,583.55 | -$65,224.45 | -12.4% |
Connect Biopharma Holdings Ltd. (CNTB) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Connect Biopharma Holdings Ltd. ever had a stock split?
Connect Biopharma Holdings Ltd. Profile
| Biotechnology Industry | Healthcare Sector | Barry D. Quart CEO | NASDAQ (NMS) Exchange | G23549101 CUSIP |
| US Country | 64 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapies aimed at treating T cell-driven inflammatory diseases. Founded in 2012 and headquartered in San Diego, California, the company focuses on leveraging its expertise in functional T cell assays to screen and identify potent product candidates. These candidates target validated immune mediators with the goal of addressing significant unmet medical needs in inflammatory disorders. Connect Biopharma's strategic approach combines the development of both small molecules and antibodies to create a diverse pipeline capable of confronting various facets of immune system dysregulation.
Products and Services
- Rademikibart (formerly CBP-201)
- Icanbelimod (formerly CBP-307)
This leading product candidate is an antibody that specifically targets interleukin-4 receptor alpha, a critical mediator in the pathogenesis of several inflammatory diseases. Designed with the intention of disabling this pathway, rademikibart has moved into Phase 3 studies, exploring its effectiveness and safety in conditions such as atopic dermatitis and asthma. The targeting of interleukin-4 receptor alpha represents a rational and scientifically backed strategy to dampen the inflammatory response characteristic of these disorders, positioning rademikibart as a potentially pivotal therapy in the landscape of immunologically driven diseases.
This oral small molecule drug functions as a modulator of Sphingosine 1-Phosphate Receptor 1, a crucial component in the immune system's ability to mediate inflammatory responses. Currently under Phase 2 clinical development, icanbelimod is being tested for its efficacy and safety in the management of ulcerative colitis and Crohn's disease, two debilitating inflammatory bowel diseases. The molecule's mechanism of action offers a targeted approach to modulating disease activity, aiming to balance immune response without compromising overall immune competence, thereby offering hope for patients with these chronic conditions.
